GLP-1 Drugs

Behind the hype of GLP-1 medications lies complex science, serious side effects and a pharmaceutical arms race.

A new study finds that people who quit weight-loss medications, including GLP-1 drugs, regain weight four times faster than people who stop dieting or exercising

The first GLP-1 pills for weight loss are hitting U.S. pharmacies. But how will they be prescribed?

A pill version of the popular GLP-1 weight-loss drug Wegovy has been green-lit for use in the U.S. Here’s what that means for health care

New WHO guidance calls for a worldwide obesity treatment “ecosystem” to ensure that GLP-1 weight-loss drugs are used fairly

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer's progression

Scientists look to genetics to explain why GLP-1 drugs work for some people but not for others

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver disease and type 2 diabetes

Some users of GLP-1 weight-loss drugs have been reporting strange changes in food preferences, such as a new dislike for meats or fried foods, and scientists are beginning to figure out why

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and accessibility. What’s keeping the pills from taking off?

Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority of people who use these drugs quit after just two years

Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known about their long-term effects